1-Anilinophthalazine | 24953-58-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-Anilinophthalazine
• 英文别名: phenyl-phthalazin-1-yl-amine；Anilinophthalazine；N-phenylphthalazin-1-amine
• CAS: 24953-58-0
• 化学式: C₁₄H₁₁N₃
• 分子量: 221.261
• InChiKey: GZLPQVREIBIVAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS<br/>[FR] ANALOGUES DE BENZOTHIOPHÈNE SUBSTITUÉS EN TANT QU'AGENTS DE DÉGRADATION SÉLECTIFS DU RÉCEPTEUR D'ŒSTROGÈNES
  申请人：UNIV ILLINOIS

  公开号：WO2019157020A1

  公开（公告）日：2019-08-15

  In one aspect, the disclosure relates to relates to substituted benzothiophene analogs which are useful as selective degraders of estrogen receptor, methods of making same, pharmaceutical compositions comprising same, and methods of treating one or more clinical conditions associated with estrogen receptor, such as a cancer, including breast cancer, or osteoporosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

  在一个方面，该披露涉及与取代苯并噻吩类似物相关的内容，这些类似物可用作雌激素受体的选择性降解剂，制备方法，包含它们的药物组合物，以及治疗与雌激素受体相关的一个或多个临床病况的方法，如癌症，包括乳腺癌，或骨质疏松症。此摘要旨在用作在特定领域进行搜索的扫描工具，并不意在限制本披露。
• [EN] KITS AND METHODS FOR TREATING CANCERS<br/>[FR] KITS ET MÉTHODES DE TRAITEMENT DES CANCERS
  申请人：SPECTRUM PHARMACEUTICALS INC

  公开号：WO2020056156A1

  公开（公告）日：2020-03-19

  A kit containing a crystalline form of a quinazoline compound. More particularly, the crystalline form is derived from the compound of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one. Also disclosed is a method of treating cancers with the crystalline form or a kit thereof.

  一种包含喹唑啉化合物的结晶形式的试剂盒。更具体地说，所述结晶形式源自1-(4-(4-(3,4-二氯-2-氟苯胺基)-7-甲氧基喹唑啉-6-氧基)哌啶-1-基)丙-2-烯-1-酮化合物。还公开了使用该结晶形式或其试剂盒治疗癌症的方法。
• Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
  申请人：PHARMACIA & UPJOHN S.p.A.

  公开号：US20030073692A1

  公开（公告）日：2003-04-17

  Compounds which are amino-phthalazinone derivatives and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本文揭示了一种氨基-邻苯二氮酮衍生物及其药学上可接受的盐，以及包含它们的制药组合物；这些化合物或组合物在治疗由于和/或与蛋白激酶活性改变有关的疾病方面具有用处，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
  申请人：Cai Sui Xiong

  公开号：US20080020985A1

  公开（公告）日：2008-01-24

  Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明披露了1-芳基氨基-菲啶嗪、4-芳基氨基苯并[d][1,2,3]三嗪及其类似物，它们有效激活半胱氨酸蛋白酶和诱导细胞凋亡。本发明的化合物在治疗各种临床病症中具有用途，这些病症中存在不受控制的异常细胞生长和扩散。
• Method of Treating Cancer
  申请人：Exelixis, Inc.

  公开号：US20140057908A1

  公开（公告）日：2014-02-27

  This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

  本发明旨在使用MET和VEGF的双重抑制剂治疗癌症，特别是去势抵抗性前列腺癌和骨转移性骨转移癌。

表征谱图